The FDA granted initial approval to Dr. Reddys for the production of a generic drug for the prevention of HIV The US Food and Drug Administration (FDA) pre-approved a generic version of the drug Lancafavir (marketed under the trademark Yaztogo by Gilead Sciences) for the prevention of HIV. Analog produced by Dr. Radis. The decision will allow the sale of the generic drug in many low- and middle-income countries and "take control of the 44-year-old AIDS epidemic, which still affects 1.3 million people a year." Dr. Radis became the first company among six to receive a license from Gilead Sciences to manufacture the drug, which has initial approval from the agency. Potentially, it could be sold in 120 countries covered by licensing agreements. The first doses of the generic will reach several countries before the end of 2026. Zambia may be among them. Dr. Radis' drug is expected to cost $40 per year. At the same time, the cost of the original drug Yaztogo in the USA is about 28 thousand dollars. Dr. Reddys receives technical and financial support from the World Health Organization, which operates under the auspices of the World Health Organization. Funding comes from a joint program with the Clinton HIV Care Initiative and the Institute for Reproductive Health and HIV at the University of the Witwatersrand in South Africa. Work on Lancafavir began back in 1992, when Wesley Sandquist first deciphered the structure of the HIV capsid. For a long time this idea did not develop, until in 2003 Sandquist demonstrated that exposure to the capsid inhibited the replication of the virus. In 2006, Gilad became interested in the concept, and the company received a patent for Lancafavir in 2013. Read us in Max Telegram VK.

The FDA granted initial approval to Dr. Reddys for the production of a generic drug for the prevention of HIV The US Food and Drug Administration (FDA) pre-approved a generic version of the drug Lancafavir (marketed under the trademark Yaztogo by Gilead Sciences) for the prevention of HIV. Analog produced by Dr. Radis. The decision will allow the sale of the generic drug in many low- and middle-income countries and "take control of the 44-year-old AIDS epidemic, which still affects 1.3 million people a year." Dr. Radis became the first company among six to receive a license from Gilead Sciences to manufacture the drug, which has initial approval from the agency. Potentially, it could be sold in 120 countries covered by licensing agreements. The first doses of the generic will reach several countries before the end of 2026. Zambia may be among them. Dr. Radis' drug is expected to cost $40 per year. At the same time, the cost of the original drug Yaztogo in the USA is about 28 thousand dollars. Dr. Reddys receives technical and financial support from the World Health Organization, which operates under the auspices of the World Health Organization. Funding comes from a joint program with the Clinton HIV Care Initiative and the Institute for Reproductive Health and HIV at the University of the Witwatersrand in South Africa. Work on Lancafavir began back in 1992, when Wesley Sandquist first deciphered the structure of the HIV capsid. For a long time this idea did not develop, until in 2003 Sandquist demonstrated that exposure to the capsid inhibited the replication of the virus. In 2006, Gilad became interested in the concept, and the company received a patent for Lancafavir in 2013. Read us in Max Telegram VK.